CXI Healthcare Announces 7.2 Billion Won Third-Party Allotment to CEO, Diluting 9.9% with Three-Year Lock-Up
CXI Healthcare has decided on a third-party allotment of 3.7 million shares at 1,955 won per share to its CEO and largest shareholder Lin Jinsheng, raising approximately 7.23 billion won for operating funds.
The issuance occurs during a trading suspension due to capital reduction and stock split, with the issue price based on the last closing price before suspension, resulting in no discount. The new shares represent a dilution of about 9.9% of the outstanding shares.
The shares acquired by the largest shareholder are subject to a statutory one-year lock-up plus an additional two-year voluntary lock-up, totaling three years of restricted resale, aimed at protecting existing shareholders and demonstrating management commitment.
Proceeds will be used for securing tea plantation facilities, labor costs, and marketing expenses to support the production and distribution of organic health foods and cosmetics.
[AI Summary]While the 9.9% dilution is a short-term burden, the no-discount pricing and three-year lock-up mitigate shareholder value erosion. The capital injection supports business normalization and long-term growth, but the stock's post-suspension performance remains a key risk.
KOSDAQ Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)
Company: CXI Healthcare Technology Group (900120)
Submission: CXI Healthcare Technology Group Limited